Patents by Inventor Marc Müller

Marc Müller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8076494
    Abstract: Disclosed is a process for the manufacture of a compound of formula (I) wherein Hal represents fluoro or chloro, and R1 and R2 represent, independently from one another, hydrogen or Hal; in which process a compound of formula (II) is converted to a corresponding alkyl, fluoroalkyl or aryl sulfonic acid ester, which is then reacted with an alkali metal nitrite in the presence of a suitable crown ether in a polar non-nucleophilic solvent at a temperature of ?10 to 50° C. to give the compound of formula (I).
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: December 13, 2011
    Assignee: Basilea Pharmaceutica AG
    Inventors: Marc Muller, Lin Xu
  • Publication number: 20110178291
    Abstract: A process for manufacturing a compound of Formula (I) which has cis-conformation and wherein R1 represents a 1-phenyl-C1-C4alkyl or 1-naphthyl-C1-C4alkyl group, wherein the phenyl or naphthyl moiety of R1 is unsubstituted or substituted with one or more C1-C4alkoxy groups and the carbon atoms in 2-, 3-, and/or 4-position of the alkyl part of R1 are, independently of the phenyl or naphthyl moiety of R1 and independently of one another, unsubstituted or substituted with C1-C4alkoxy and/or silyloxy or, preferably, are unsubstituted or substituted with one C1-C4alkoxy group and/or silyloxy group per carbon atom, and R2 represents a C1-C6alkyl group or an unsubstituted or substituted benzyl group, in which process a compound of Formula (II) wherein R3 represents a C1-C6alkyl group or an unsubstituted or substituted benzyl group, and R1 and R2 have the same meaning as in formula (I); is treated with a base at a temperature of 0° C.
    Type: Application
    Filed: September 15, 2008
    Publication date: July 21, 2011
    Inventors: Marc Muller, Xiaoping Wu, Lin Xu
  • Publication number: 20110021794
    Abstract: Disclosed is a process for the manufacture of a compound of formula (I) wherein Hal represents fluoro or chloro, and R1 and R2 represent, independently from one another, hydrogen or Hal; in which process a compound of formula (II) is converted to a corresponding alkyl, fluoroalkyl or aryl sulfonic acid ester, which is then reacted with an alkali metal nitrite in the presence of a suitable crown ether in a polar non-nucleophilic solvent at a temperature of ?10 to 50° C. to give the compound of formula (I).
    Type: Application
    Filed: August 31, 2010
    Publication date: January 27, 2011
    Inventors: Marc Muller, Lin Xu
  • Patent number: 7816537
    Abstract: Disclosed is a process for the manufacture of a compound of formula (I) wherein Hal represents fluoro or chloro, and R1 and R2 represent, independently from one another, hydrogen or Hal; in which process a compound of formula (II) is converted to a corresponding alkyl, fluoroalkyl or aryl sulfonic acid ester, which is then reacted with an alkali metal nitrite in the presence of a suitable crown ether in a polar non-nucleophilic solvent at a temperature of ?10 to 50° C. to give the compound of formula (I).
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: October 19, 2010
    Assignee: Basilea Pharmaceutica AG
    Inventors: Marc Muller, Lin Xu
  • Publication number: 20090299073
    Abstract: Disclosed is a process for the manufacture of a Compound of formula (I) wherein Hal represents fluoro or chloro, and R1 and R2 represent, independently from one another, hydrogen or Hal; in which process a Compound of formula (II) is converted to a corresponding alkyl, fluoroalkyl or aryl sulfonic acid ester, which is then reacted with an alkali metal nitrite in the presence of a suitable crown ester in a polar non-nucleophilic solvent at a temperature of ?10 to 50° C. to give the Compound of formula (I).
    Type: Application
    Filed: November 29, 2006
    Publication date: December 3, 2009
    Inventors: Marc Muller, Lin Xu
  • Patent number: 7253281
    Abstract: The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a]indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.
    Type: Grant
    Filed: June 28, 2005
    Date of Patent: August 7, 2007
    Assignees: Hoffmann-La Roche Inc., Vernalis Research Limited
    Inventors: Jonathan Mark Bentley, Paul Hebeisen, Patrizio Mattei, Marc Muller, Hans Richter, Stephan Roever, Sven Taylor
  • Publication number: 20070106076
    Abstract: The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a] indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.
    Type: Application
    Filed: January 3, 2007
    Publication date: May 10, 2007
    Inventors: Jonathan Bentley, Paul Hebeisen, Patrizio Mattei, Marc Muller, Hans Richter, Stephan Roever, Sven Taylor
  • Patent number: 7064199
    Abstract: The invention is concerned with a process for the manufacture of vinylpyrrolidinone-cephalosporin derivatives from 3-amino-pyrrolidine derivatives of the formula wherein R1 signifies hydrogen or an amino protecting group; Z signifies hydrogen or an amino protecting group; and * represents a center of chirality.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: June 20, 2006
    Assignee: Basilea Pharmaceutica AG
    Inventors: Marc Muller, Milan Soukup
  • Publication number: 20050239789
    Abstract: The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a]indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.
    Type: Application
    Filed: June 28, 2005
    Publication date: October 27, 2005
    Inventors: Jonathan Bentley, Paul Hebeisen, Patrizio Mattei, Marc Muller, Hans Richter, Stephan Roever, Sven Taylor
  • Patent number: 6933387
    Abstract: The present invention is directed to 1,2,3,4,10,10a-hexahydropyrazino [1,2-a]indole derivatives of formula (I): as well as pharmaceutically acceptable salts, hydrates and esters thereof, wherein the substituents have the meanings provided in the specification. Compounds of the present invention may be used in the treatment or prevention of obesity or Type II diabetes.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: August 23, 2005
    Assignees: Hoffmann-La Roche Inc., Vernalis Research Limited
    Inventors: Jonathan Mark Bentley, Paul Hebeisen, Marc Muller, Hans Richter, Stephan Roever
  • Patent number: 6872836
    Abstract: The invention is concerned with a process for the manufacture of 3-amino-pyrrolidine derivatives of the formula wherein R1 signifies hydrogen or an amino protecting group; Z signifies hydrogen or an amino protecting group; and * represents a center of chirality. 3-Amino-pyrrolidine derivatives, especially optically active 3-amino-pyrrolidine derivatives, are intermediates for the production of agrochemicals and of pharmaceutically active substances such as, for example, of vinylpyrrolidinone-cephalosporin derivatives.
    Type: Grant
    Filed: July 29, 2003
    Date of Patent: March 29, 2005
    Assignee: Basilea Pharmaceutica AG, A Swiss Company
    Inventors: Marc Muller, Milan Soukup
  • Patent number: 6844345
    Abstract: The present invention provides piperazine derivatives in accordance with formula (I) as well as salts, hydrates and esters thereof. The substituent designations are as provided in the specification. The compounds of the present invention can be used in the treatment of type II diabetes or obesity.
    Type: Grant
    Filed: March 7, 2002
    Date of Patent: January 18, 2005
    Assignees: Hoffman-La Roche Inc., Vernal Research Limited
    Inventors: Paul Hebeisen, Patrizio Mattei, Marc Muller, Hans Richter, Stephan Roever, Sven Taylor
  • Patent number: 6821980
    Abstract: The invention relates to substituted 5-benzyl-2,4-diaminopyrimidines of general formula (A) wherein R1 is C2-C3 alkyl an R2 is heterocyclyl, phenyl or naphthyl, bonded by one of its C-atoms and R3 is C2-C6 alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclylalkyl, alkylsulfonyl, cycloalkylsulfonyl, cycloalkylalkylsulfamoyl, heterocyclysylfonyl, heterocyclylalkylsulfonyl or dialkylsulfamoyl; wherein alkyl, cycloalkyl and alyenyl can carry up to 6 carbon atoms alone or in compositions and can carry up to 6 ring members heterocyclically, alone, or in compositions and the groups R2 and R3 can be substituted; and to acid addition salts of compounds. The invention also relates to a method for producing the above 5-benzyl-2,4-diaminopyrimidines, to the intermediate. products that are produced, to corresponding medicaments and to the use of 5-benzyl-2,4-diaminopyrimidines as medicinal preparations.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: November 23, 2004
    Assignee: Basilea Pharmaceutica AG
    Inventors: Philippe Guerry, Peter Mohr, Marc Muller, Werner Mueller, Philippe Pflieger
  • Publication number: 20040127703
    Abstract: The invention is concerned with a process for the manufacture of vinylpyrrolidinone-cephalosporin derivatives from 3-amino-pyrrolidine derivatives of the formula 1
    Type: Application
    Filed: December 22, 2003
    Publication date: July 1, 2004
    Inventors: Marc Muller, Milan Soukup
  • Publication number: 20040077728
    Abstract: Disclosed are retiferol derivatives of formula (I): wherein X is >C═CH2 or —CH2—; Y and Z are independently of each other hydrogen, fluorine or hydroxy; A is —O(CH2)3—, —(CH2)2-(1,2-C6H4)—, —CH═CH—(1,2-C6H4)—, —C═C—(1,2C6H4)—, —(CH2)2—CO—, —CH2—O—CO—, —CH2NHCO—, or —CH2NHCOCH2—; R1 is C1-C5-alkyl; R2 and R3 are independently of each other alkyl or perfluoroalkyl; and R4 is hydrogen, hydroxy, C1-C5-alkyl or C1-C5-alkyl or C1-C5-alkoxy; the use of such compounds to treat or present hyperproliferative skin diseases such as psoriasis, basal cell carcinomas, disorders of keratinization and keratosis; neoplastic diseases; disorders of the sebaceous glands such as acne and seborrhoic dermatitis; the use of these compounds in reversing the conditions associated with photodamage, particularly for the oral or topical treatment of the skin damaged through sun exposur
    Type: Application
    Filed: December 4, 2003
    Publication date: April 22, 2004
    Inventors: Pierre Barbier, Franz W Bauer, Peter Mohr, Marc Muller, Wolfgang Pirson
  • Publication number: 20040034236
    Abstract: The invention is concerned with a process for the manufacture of 3-amino-pyrrolidine derivatives of the formula 1
    Type: Application
    Filed: July 29, 2003
    Publication date: February 19, 2004
    Inventors: Marc Muller, Milan Soukup
  • Publication number: 20030216401
    Abstract: The present invention is directed to 1,2,3,4,10,10a,-hexahydro-pyrazino[1,2-a]indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.
    Type: Application
    Filed: March 25, 2003
    Publication date: November 20, 2003
    Inventors: Jonathan Mark Bentley, Paul Hebeisen, Marc Muller, Hans Richter, Stephan Roever
  • Publication number: 20020169163
    Abstract: Piperazine derivatives, as well as pharmaceutically acceptable salts, solvates and esters thereof, can be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, type II diabetes, obesity and sleep apnoea.
    Type: Application
    Filed: March 7, 2002
    Publication date: November 14, 2002
    Inventors: Paul Hebeisen, Patrizio Mattei, Marc Muller, Hans Richter, Stephan Roever, Sven Taylor
  • Publication number: 20020035110
    Abstract: The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a] indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.
    Type: Application
    Filed: July 25, 2001
    Publication date: March 21, 2002
    Inventors: Jonathan M. Bentley, Paul Hebeisen, Marc Muller, Hans Richter, Stephan Roever
  • Patent number: 6357034
    Abstract: A method of communicating data in a system having a plurality of transmitters each adapted to transmit a radio signal, and a receiver situated at a distance from the transmitters to receive and process the signals transmitted by the transmitters, information for transmission being subdivided into N-bit symbols, the method consisting in: giving a numerical value to each symbol; and compressing the data using a CHIP encoding technique in which the values of the symbols are transposed to an encoded value having x digits in a base B, each digit subsequently being represented in the form of n chips, the base B, the number n of chips, and the number x of digits for an encoded value satisfying the following conditions: B≦2&ngr; and 2N≦B&xgr;  so that the total number of chips x.n representing the coded value is less than 2.N.
    Type: Grant
    Filed: January 16, 1999
    Date of Patent: March 12, 2002
    Assignee: Schlumberger Industries, S.A.
    Inventors: Marc Muller, Patrick Moreau, Philippe Godlewski